Aperio Group LLC decreased its holdings in shares of Qiagen NV (NASDAQ:QGEN) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 206,183 shares of the company’s stock after selling 2,162 shares during the quarter. Aperio Group LLC owned approximately 0.09% of Qiagen worth $6,377,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the stock. Ameriprise Financial Inc. bought a new stake in shares of Qiagen in the second quarter worth $2,930,000. Vanguard Group Inc. boosted its position in shares of Qiagen by 7.0% in the second quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock valued at $202,986,000 after acquiring an additional 394,201 shares during the period. Virtu KCG Holdings LLC boosted its position in shares of Qiagen by 59.0% in the second quarter. Virtu KCG Holdings LLC now owns 11,267 shares of the company’s stock valued at $378,000 after acquiring an additional 4,179 shares during the period. QS Investors LLC lifted its position in Qiagen by 1.7% during the second quarter. QS Investors LLC now owns 13,594 shares of the company’s stock worth $456,000 after purchasing an additional 226 shares during the period. Finally, State Street Corp increased its stake in shares of Qiagen by 2.1% in the second quarter. State Street Corp now owns 2,330,061 shares of the company’s stock valued at $78,130,000 after buying an additional 48,679 shares during the period. Institutional investors and hedge funds own 62.23% of the company’s stock.
A number of analysts have weighed in on QGEN shares. TheStreet raised shares of Qiagen from a “c+” rating to a “b+” rating in a research report on Tuesday, November 7th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Friday, December 1st. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. Goldman Sachs Group started coverage on Qiagen in a research note on Monday, January 29th. They issued a “buy” rating and a $39.00 price target on the stock. Finally, Cowen restated a “hold” rating and issued a $34.00 price target on shares of Qiagen in a research report on Thursday, December 21st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $35.33.
Qiagen declared that its Board of Directors has initiated a share buyback plan on Wednesday, January 31st that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://stocknewstimes.com/2018/02/20/aperio-group-llc-sells-2162-shares-of-qiagen-nv-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.